Skip to content

Certara

US · CERT #2994 by market cap Listed 2020
8.96 -0.31 -3.34%
Live - 5344 symbols - heartbeat 157s ago · 2026-10-08 04:20
Pre-market 8.92 -0.49%
After-hours 8.92 -0.40%
Overnight 9.10 +1.56%
Market cap
1.37B
P/B
1.41
EPS
-0.01
Reader sentiment Are you bullish or bearish on CERT?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 1.46 Cheap vs history 18th percentile
5-year average 2.36 · #16 of 41 in Health Information Services
P/E ratio -21.07 Expensive vs history 71st percentile
5-year average -92.02 · forward -301.84
P/S ratio 3.35 Cheap vs history 15th percentile
5-year average 7.31 · forward 3.73 · #26 of 42 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
Certara (CERT) 1.37B -20.36 1.41 0.00%
Veeva Systems (VEEV) 45.74B 46.31 6.15 0.00%
Tempus AI (TEM) 12.69B -48.85 28.53 0.00%
BrightSpring Health Services (BTSG) 12.62B 38.67 6.16 0.00%
Hinge Health (HNGE) 7.90B 73.14 22.93 0.00%
HealthEquity (HQY) 7.60B 33.18 3.82 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value12.97 Economic moatNone UncertaintyHigh

Trading 44.8% below Morningstar's fair value estimate.

Fair value

On the surface, Certara Inc appears cheap due to significant downward price pressure over the past year. To incorporate the risk associated with a potential value trap, we have capped its rating at 3 stars. The stock currently trades at a 29% discount to our quantitative fair value estimate of $12.97 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 67.7%, which sits in the top 45% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

Alternatively, the firm's lack of growth is potentially concerning. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. The firm's EBIT 3-year growth, for example, sits in the bottom 1% globally. Earnings before interest and taxes has exhibited poor growth over the last three years. The future could be difficult for the firm, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 04:20:42 · For reference only, not investment advice and not tailored to your situation.